Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal‐P)

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.12121PMID 23627775
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1)

  2014cited by this paper
• Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin

  2013cited by this paper
• Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

  2013cited by this paper
• Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin

  2013cited by this paper
• Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

  2013cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy

  2012cited by this paper
• Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide inMonotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

  2012cited by this paper
• Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)*

  2012cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

  2011influential reference
• Lixisenatide for type 2 diabetes mellitus

  2011cited by this paper
• Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes

  2011cited by this paper
• The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review

  2011cited by this paper
• Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

  2010cited by this paper
• Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.

  2010cited by this paper
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Pioglitazone: mechanism of action.

  2001cited by this paper
• Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

  1992influential reference

• Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.

  2026cites this paper
• Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis

  2025cites this paper
• Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis

  2025cites this paper
• Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.

  2025cites this paper
• Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.

  2025cites this paper
• Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis

  2025cites this paper
• Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database

  2024cites this paper
• Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials.

  2024cites this paper
• Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials.

  2024cites this paper
• Insights on Dietary Polyphenols as Agents against Metabolic Disorders: Obesity as a Target Disease

  2023cites this paper
• Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus.

  2023cites this paper
• Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?

  2023cites this paper
• A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications

  2023influential citation
• Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials

  2023cites this paper
• The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study

  2022cites this paper
• Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis

  2022cites this paper
• Pharmacotherapy of type 2 diabetes: An update and future directions.

  2022cites this paper
• A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes

  2022cites this paper
• Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: a network meta-analysis.

  2021cites this paper
• Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis

  2021cites this paper
• Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

  2020cites this paper
• Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid

  2020cites this paper
• GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.

  2020cites this paper
• Tinjauan atas Glucagon-like peptide-1 receptor agonist

  2020cites this paper
• Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus

  2020cites this paper
• Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost–Utility Analysis

  2020cites this paper
• Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis

  2019cites this paper
• Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study

  2019cites this paper
• Diabetic Pharmacotherapies in Kidney Disease

  2019cites this paper
• Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

  2019cites this paper
• GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials

  2019cites this paper
• Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?

  2018cites this paper
• Battle of GLP-1 delivery technologies.

  2018cites this paper
• A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs

  2018cites this paper
• A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

  2018cites this paper
• Treatment with GLP-1 Receptor Agonists

  2018cites this paper
• PRISMA—efficacy and safety of lixisenatide for type 2 diabetes mellitus

  2018cites this paper
• GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

  2018cites this paper
• Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.

  2018cites this paper
• Comparisons of diabetic retinopathy events associated with glucose‐lowering drugs in patients with type 2 diabetes mellitus: A network meta‐analysis

  2018cites this paper
• Lixisenatide, a Once‐Daily Prandial Glucagon‐Like Peptide‐1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes

  2017cites this paper
• Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring

  2017cites this paper
• Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment

  2017cites this paper
• Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials

  2017cites this paper
• Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open‐label, multicenter study

  2017cites this paper
• Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus

  2017cites this paper
• Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.

  2017cites this paper
• Lixisenatide

  2017cites this paper
• Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists

  2017cites this paper
• Lixisenatide as add‐on treatment among patients with different β‐cell function levels as assessed by HOMA‐β index

  2017cites this paper
• A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes

  2017cites this paper
• Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.

  2017cites this paper
• Targeting orphan G protein‐coupled receptors for the treatment of diabetes and its complications: C‐peptide and GPR146

  2017cites this paper
• Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.

  2017cites this paper
• The role of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes

  2017cites this paper
• Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study

  2017cites this paper
• Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus

  2017cites this paper
• Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta‐analysis from the GetGoal programme

  2017cites this paper
• Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis

  2017cites this paper
• Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal‐L‐C randomized trial

  2017cites this paper
• WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.

  2017cites this paper
• Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management

  2017influential citation
• Lixisenatide: A New Option for Managing Type 2 Diabetes

  2017cites this paper
• The efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin : the GetGoal-LC randomized trial

  2017cites this paper
• Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis

  2017cites this paper
• Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon.

  2016cites this paper
• Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness

  2016cites this paper
• Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.

  2016cites this paper
• Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.

  2016cites this paper
• Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials

  2016cites this paper
• Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future

  2016cites this paper
• Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis

  2016cites this paper
• A systematic review of the safety of incretin-based therapies in type 2 diabetes

  2016cites this paper
• Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

  2016cites this paper
• Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis

  2016cites this paper
• The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.

  2016cites this paper
• Glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus: a brief review

  2016cites this paper
• Role of glucagon-like peptide 1 receptor agonists in management of obesity.

  2016cites this paper
• Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care

  2016cites this paper
• Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

  2016cites this paper
• Genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

  2016cites this paper
• Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

  2016cites this paper
• Dulaglutid: GLP-1-Rezeptoragonist zur einmal wöchentlichen Therapie des Typ-2-Diabetes

  2016cites this paper
• Lixisenatide: a once-daily glucagon-like peptide-1 receptor agonist

  2016cites this paper
• Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis GLP-1 RAs treatments in diabetes

  2016cites this paper
• Adverse effects of incretin‐based therapies on major cardiovascular and arrhythmia events: meta‐analysis of randomized trials

  2016cites this paper
• Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus

  2015cites this paper
• Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme

  2015cites this paper
• Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study

  2015cites this paper
• Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.

  2015influential citation
• Potential side effects to GLP-1 agonists: understanding their safety and tolerability

  2015cites this paper
• Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes.

  2015cites this paper
• Glucagon‐like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective

  2015cites this paper
• Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy

  2015cites this paper
• Incretin-based therapies for obesity treatment.

  2015cites this paper
• The role of GLP-1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

  2015cites this paper
• Pharmacologic Approach to Type 2 Diabetes in Obese Patients

  2015cites this paper
• The role of GLP‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

  2015cites this paper
• Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects

  2015cites this paper